Ben Venue Announces Divestiture of Assets of Bedford Laboratories to Hikma
News May 29, 2014
Ben Venue Laboratories. Inc. has announced that the company has signed an asset purchase agreement for the sale of the assets of Bedford Laboratories, Ben Venue’s U.S. injectable generics business to Hikma Pharmaceuticals PLC (“Hikma”).
Bedford Laboratories is a leading provider of generic sterile injectable medicines in the U.S., with a focus on acute-care hospitals, group purchasing organizations and oncology treatment centers.
Under the terms of the agreement, Hikma will be acquiring Bedford Laboratories’ assets, including a large product portfolio, intellectual property rights, contracts for products marketed under license, raw material inventories, a strong research and development (R&D) and business development pipeline, and a number of employees across key business functions, such as R&D, sales and marketing, business development and regulatory affairs.
“We believe that this is a positive development, allowing Hikma to leverage its existing infrastructure and manufacturing capabilities to re-introduce important products to the U.S. market, bringing significant benefit to patients,” said Paul R. Fonteyne, U.S. Country Managing Director, President and CEO of Boehringer Ingelheim USA Corporation and Chairman, Ben Venue Board of Directors. “For more than 20 years, Bedford Laboratories and its product portfolio have been of great value to patients, customers and the marketplace. As part of Hikma, the Bedford team will remain focused on strengthening its relationships with customers and continuing to serve the needs of patients.”
“I am very excited to be acquiring an impressive portfolio of Bedford’s products and deep pipeline, which will significantly increase the scale and scope of our rapidly growing U.S. Injectables business. Our focus on bringing back critical products to the market that are currently in short supply will bring significant benefit to patients,” said Said Darwazah, Chief Executive Officer of Hikma. “I am confident that we have the technical capabilities and manufacturing expertise to successfully re-launch Bedford’s products in the near term. Our experience in integrating previous acquisitions will help to ensure a smooth integration.”
In addition, Hikma has entered into an exclusivity arrangement with the Boehringer Ingelheim Group to potentially acquire substantially all of the assets of the Ben Venue manufacturing facility, subject to due diligence and customary approvals in the U.S. and the U.K.
Bank of America Merrill Lynch acted as the financial advisor, and Covington & Burling LLP acted as counsel, to Ben Venue.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Cocaine Use Alters Gene Expression in Brain Reward CircuitsNews
A study in Biological Psychiatry investigates transcriptome-wide alterations in response to cocaine self-administration in mice.